Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG505 SOSIP GT1.1 gp140
- Development stage
- Phase 1
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
BG505 SOSIP GT1.1 gp140 is an experimental HIV-1 vaccine candidate designed as a soluble, cleavage-competent trimeric envelope glycoprotein (gp140) based on the HIV-1 strain BG505 and engineered for germline-targeting to elicit broadly neutralizing antibody (bnAb) precursors against conserved epitopes of the virus[3][4][6]. The vaccine is administered intramuscularly and formulated with an adjuvant to enhance immune response[3][5]. It aims to induce B cell responses capable of maturing into protective bnAbs by targeting the CD4 binding site (CD4bs) and other conserved regions on the HIV envelope protein[4][6]. The immunogen was developed using structure-based design approaches to optimize its ability to engage diverse naive B cell receptors relevant for bnAb development[4][6]. Primary indication is prevention of HIV infection.
- Other names
- BG505 SOSIP.GT1.1BG-505 SOSIP.GT1.1BG 505 SOSIP.GT1.1GT1.1GT-1.1GT 1.1
02
Targets
BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on BG505 SOSIP GT1.1 gp140.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG505 SOSIP GT1.1 gp140.